

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.

叮噹健康科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 09886)

**(1) CHANGE OF NON-EXECUTIVE DIRECTOR; AND
(2) CHANGE IN COMPOSITION OF THE
NOMINATION COMMITTEE**

The Board hereby announces that, with effect from May 30, 2025:

1. Ms. CAI Li has tendered her resignation as a non-executive Director of the Company and ceased to be a member of the Remuneration Committee;
2. Ms. LI Chuheng has been appointed as a non-executive Director of the Company and a member of the Remuneration Committee and Nomination Committee; and
3. Mr. JIANG Shan has been appointed as a member of the Nomination Committee of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) hereby announces the following changes of the Board.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Ms. CAI Li (“**Ms. CAI**”) has tendered her resignation as a non-executive Director of the Company with effect from May 30, 2025 due to her intention to focus on other business engagements. Ms. CAI has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders (the “**Shareholders**”) of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Ms. CAI for her valuable contribution to the Company during her tenure of office.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. LI Chuheng (“**Ms. LI**”) has been appointed as a non-executive Director of the Company and a member of the Remuneration Committee and Nomination Committee with effect from May 30, 2025.

The biographical details of Ms. LI are set out as follows:

Ms. LI, aged 33, joined TPG Capital in January 2022 and is recently serving as the vice president of TPG Haihua (Shanghai) Equity Investment Management Co., Ltd., responsible for healthcare investments in Greater China for TPG Capital, a leading global alternative asset firm. Ms. LI has served as a non-executive director of Shanghai Ark Biopharmaceutical Co., Ltd. since February 2025.

From August 2020 to November 2021, Ms. LI served as the senior investment manager of Shanghai Yunfeng Investment Management Co., Ltd. From January 2019 to August 2020, Ms. LI served as an investment manager of Hangzhou Shengding Jikang Equity Investment Management Co., Ltd., a healthcare investment platform under Sino-Ocean Capital. From June 2016 to June 2018, Ms. LI served as an investment manager of Shanghai Guijing Investment Management (Limited Partnership), a merger and acquisition fund under Jingfeng Pharmaceutical.

Ms. LI obtained a master’s degree in chemistry from Brown University in Rhode Island, the United States in May 2016, a bachelor’s degree in chemistry from University of Birmingham in the United Kingdom in July 2014, and a bachelor’s degree in chemistry from Sun Yat-sen University in September 2014.

Ms. LI has entered into a letter of appointment with the Company for an initial term of three years with effect from May 30, 2025, which is renewable automatically for successive terms of three years commencing on the day after the expiry of the then existing term and may be terminated by not less than one month’s notice in writing served by either party on the other. Ms. LI will hold office until the first annual general meeting of the Company after her appointment and be eligible for re-election in accordance with the articles of association of the Company. Ms. LI does not receive any director’s fees as a non-executive Director.

Save as disclosed above, as at the date of this announcement, Ms. LI (a) does not have any interests in the shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (b) does not hold any directorships in any other listed public companies in Hong Kong or overseas in the last three years preceding the date of her appointment, and does not hold any other major appointments and professional qualifications; (c) does not have any relationships with any Director, senior management, substantial shareholder or controlling shareholder of the Company (as defined under the Listing Rules); and (d) does not hold any other position with the Company or any members of the Group.

Save as disclosed above, there is no other matters which need to be brought to the attention of the Shareholders of the Company regarding the appointment of Ms. LI or any other information which is required to be disclosed pursuant Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to take this opportunity to express its warm welcome to Ms. LI for joining the Board.

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The Board further announces that Mr. JIANG Shan, an independent non-executive Director, has been appointed as a member of the Nomination Committee of the Company with effect from May 30, 2025.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
Chairman
YANG WENLONG

Hong Kong, May 30, 2025

As at the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei, Mr. YU Qinglong and Mr. YANG Yibin, the non-executive Director is Ms. LI Chuheng, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.